Education
About Us
Working with TipRanks
Follow Us
Acrux Limited (AU:ACR)
ASX:ACR
ACR Stock Chart & Stats
AU$0.02
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.02
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.03
Previous CloseN/A
Volume88.57K
Average Volume (3M)120.95K
Market Cap
AU$4.93M
Enterprise ValueAU$7.62M
Total Cash (Recent Filing)AU$863.00K
Total Debt (Recent Filing)AU$3.63M
Price to Earnings (P/E)9.3
Beta-0.19
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding410,608,520
10 Day Avg. Volume76,863
30 Day Avg. Volume120,955
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)5.51
Price to Sales (P/S)4.73
P/FCF Ratio-1.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Asset-light Licensing ModelAcrux’s licensing-and-royalty model creates recurring, contract-driven revenue streams with low incremental manufacturing and sales capex. Over the medium term this supports scaling without heavy fixed costs, preserves cash if partners execute, and aligns risk-sharing with licensees.
Recent Top-line AccelerationSizable revenue growth in 2025 indicates improving commercial traction for licensed products and/or milestone recognition. Durable top-line momentum can compound royalty income and improve negotiating leverage with partners, supporting longer-term revenue visibility if growth is sustained.
Specialized IP And Formulation ExpertiseAcrux’s niche expertise and owned IP in transdermal/topical delivery creates barriers to entry and makes it an attractive technology partner for pharma firms. Durable competitive advantage from proprietary formulations can underpin future licensing deals and long-term royalty streams.
Bears Say
High LeverageA debt-to-equity ratio of 3.55 signals material leverage that limits financial flexibility. Over 2-6 months this raises refinancing and covenant risk, increases interest burden, and constrains the company’s ability to fund development or pursue opportunistic licensing without dilutive financing or asset sales.
Negative Operating And Free Cash FlowPersistently negative operating and free cash flows indicate the business consumes cash and relies on financing, milestones, or partner payments for liquidity. This structural cash deficit can force dilution or costly borrowing and weakens the company’s capacity to sustain R&D or commercial support long-term.
Ongoing Losses And Weak ProfitabilityDespite revenue gains, persistent negative margins and net losses reflect an inability to convert top-line into sustainable profits. Over months this hampers internal funding for projects, undermines return on equity, and makes reliance on intermittent milestone receipts or external capital more likely.
Acrux News
ACR FAQ
What was Acrux Limited’s price range in the past 12 months?
Acrux Limited lowest share price was AU$0.01 and its highest was AU$0.03 in the past 12 months.
What is Acrux Limited’s market cap?
Acrux Limited’s market cap is AU$4.93M.
When is Acrux Limited’s upcoming earnings report date?
Acrux Limited’s upcoming earnings report date is Aug 21, 2026 which is in 160 days.
How were Acrux Limited’s earnings last quarter?
Acrux Limited released its earnings results on Feb 24, 2026. The company reported AU$0 earnings per share for the quarter, the consensus estimate of N/A by AU$0.
Is Acrux Limited overvalued?
According to Wall Street analysts Acrux Limited’s price is currently Overvalued.
Does Acrux Limited pay dividends?
Acrux Limited pays a Annually dividend of AU$0.06 which represents an annual dividend yield of N/A. See more information on Acrux Limited dividends here
What is Acrux Limited’s EPS estimate?
Acrux Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Acrux Limited have?
Acrux Limited has 410,608,520 shares outstanding.
What happened to Acrux Limited’s price movement after its last earnings report?
Acrux Limited reported an EPS of AU$0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Acrux Limited?
Currently, no hedge funds are holding shares in AU:ACR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Acrux Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bearish
AU:ACR Sentiment 70%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
-211.88%
Trailing 12-Months
Asset Growth
-34.57%
Trailing 12-Months
Company Description
Acrux Limited
Acrux Limited (ACR) is a biopharmaceutical company based in Australia, specializing in the development and commercialization of innovative drug delivery technologies and pharmaceutical products. The company operates primarily in the healthcare sector, focusing on transdermal delivery systems, which enable medications to be absorbed through the skin. Acrux's core products include various transdermal patches and formulations designed to improve patient adherence and therapeutic outcomes in areas such as hormone replacement therapy and pain management.
Technical Analysis
Living Cell Technologies
―
Invex Therapeutics Ltd.
―
Chimeric Therapeutics Ltd.
―
Neuroscientific Biopharmaceuticals Ltd.
―
Memphasys Ltd
―
Options Prices
Currently, No data available
---